GB004

DRUG2 trials

Sponsors

GB004, Inc., a wholly owned subsidiary of Gossamer Bio, Inc., GB004, Inc.

Conditions

Ulcerative Colitis

Phase 1

GB004 in Adult Subjects With Active Ulcerative Colitis

CompletedNCT03860896

GB004, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.Ulcerative Colitis

Start: 2019-04-24End: 2019-12-17Updated: 2020-01-14

Phase 2

A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC)

TerminatedNCT04556383

GB004, Inc.Ulcerative Colitis

Start: 2020-10-19End: 2022-06-01Updated: 2023-08-01

Related Papers

Randomised clinical trial: a phase 1b study of GB004, an oral HIF‐1α stabiliser, for treatment of ulcerative colitis

Alimentary Pharmacology & Therapeutics2022-01-1030 citations

P059 GB004 drives protective effects on immune cells and epithelial cells using human ex vivo monolayer and co-culture systems

Journal of Crohn s and Colitis2021-05-013 citations

DOP05 Target engagement and pharmacodynamic biomarker analysis following treatment with the oral gut-targeted HIF-1α stabilizer GB004 in a Phase 1b trial in Active Ulcerative Colitis

Journal of Crohn s and Colitis2021-05-011 citations

P066 GB004, A NOVEL GUT-TARGETED PROLYL HYDROXYLASE INHIBITOR FOR INFLAMMATORY BOWEL DISEASE: FIRST-IN-HUMAN, MUTLIPLE-DOSE STUDY IN HEALTHY SUBJECTS WITH GUT BIOPSIES

Inflammatory Bowel Diseases2020-01-015 citations

P540 GB004, a novel prolyl hydroxylase inhibitor for inflammatory bowel disease, leads to gut-targeted HIF-1α pathway engagement in a multiple-dose study in healthy subjects

Journal of Crohn s and Colitis2020-01-012 citations

P034 GB004, a novel gut-targeted prolyl hydroxylase inhibitor, induces HIF-1α target genes and is efficacious in mouse colitis

Journal of Crohn s and Colitis2020-01-011 citations

P051 Phase 1a Safety and Pharmacokinetic Effects of GB004, a Novel Prolyl Hydroxylase Inhibitor and Potential Therapy for Inflammatory Bowel Disease

The American Journal of Gastroenterology2019-12-013 citations